BELLUS Health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need.

Its pipeline of projects includes the Company’s lead drug candidate BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. 

BLU-5937 is a potent, highly selective, orally bioavailable small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BELLUS Health announced on July 9, 2018 the initiation of healthy subjects dosing in a Phase 1 clinical study for BLU-5937 for the treatment of chronic cough. Results of the Phase 1 clinical study are expected in the fourth quarter of 2018. Preclinical studies demonstrated that BLU-5937 is a highly selective P2X3 antagonist exhibiting a potent anti-tussive effect without affecting taste perception, with an excellent safety profile. BLU-5937 has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies. 

BELLUS Health also has economic interests in other partnered clinical-stage drug development programs.

BELLUS Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.

Share this

Sign up for email alerts

Email Address *
 
Enter the code shown above.